Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (7277)	9/24/1998 1:38:00 AM
From: Slugger	Read Replies (2) \| Respond to of 17367

<<Isn't the answer that the trial was designed for 2 years and the DSMB sees no safety reason to discontinue it, so why not let it go to completion? >> My understanding is that this is an extra review just prior to the planned completion of the trial in December. From XOMA web site: "They also requested an additional review shortly before completion of enrollment." <<Isn't a further review exactly what Xoma would want as a last resort if the DSMB is not seeing efficacy? >> It also says "They" meaning this was requested by the DSMB not XOMA.